These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 8743511

  • 1. Antihypertensive agents and renal protection: calcium channel blockers.
    Saruta T, Kanno Y, Hayashi K, Konishi K.
    Kidney Int Suppl; 1996 Jun; 55():S52-6. PubMed ID: 8743511
    [Abstract] [Full Text] [Related]

  • 2. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
    Ishimitsu T, Honda T, Ohta S, Akashiba A, Takahashi T, Kameda T, Yoshii M, Minami J, Takahashi M, Ono H, Matsuoka H.
    Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
    [Abstract] [Full Text] [Related]

  • 3. Does combined therapy of Ca-channel blocker and angiotensin converting enzyme inhibitor exceed monotherapy in renal protection against hypertensive injury in rats?
    Kanno Y, Okada H, Suzuki H, Ikenaga H, Ishii N, Itoh H, Saruta T.
    Clin Exp Hypertens; 1996 Feb; 18(2):243-56. PubMed ID: 8869003
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Blood pressure and alpha-vascular reactivity in hypertensive rats treated with amlodipine and dietary Ca.
    Civantos B, Aleixandre A.
    Eur J Pharmacol; 2004 Apr 05; 489(1-2):101-10. PubMed ID: 15063161
    [Abstract] [Full Text] [Related]

  • 6. Renal effects of calcium antagonists with special reference to manidipine hydrochloride.
    Rodicio JL.
    Blood Press Suppl; 1996 Apr 05; 5():10-5. PubMed ID: 8973787
    [Abstract] [Full Text] [Related]

  • 7. Ca2+ channel subtypes and pharmacology in the kidney.
    Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T.
    Circ Res; 2007 Feb 16; 100(3):342-53. PubMed ID: 17307972
    [Abstract] [Full Text] [Related]

  • 8. Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial.
    Halimi JM, Giraudeau B, Buchler M, Al-Najjar A, Etienne I, Laouad I, Bruyère F, Lebranchu Y.
    Clin Transplant; 2007 Feb 16; 21(2):277-84. PubMed ID: 17425758
    [Abstract] [Full Text] [Related]

  • 9. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, Holdaas H, Krcmery S, Kobalava Z, Amlodipine Versus Enalapril in Renal failure (AVER) Study Group.
    Clin Ther; 2008 Mar 16; 30(3):482-98. PubMed ID: 18405787
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A comparative study of morphological changes in spontaneously hypertensive rats and normotensive Wistar Kyoto rats treated with an angiotensin-converting enzyme inhibitor or a calcium-channel blocker.
    Saleh FH, Jurjus AR.
    J Pathol; 2001 Mar 16; 193(3):415-20. PubMed ID: 11241424
    [Abstract] [Full Text] [Related]

  • 12. Renal protective effects of amlodipine on partially nephrectomized spontaneously hypertensive rats fed a high-salt diet.
    Kanno Y, Suzuki H, Okada H, Saruta T.
    J Cardiovasc Pharmacol; 1994 Mar 16; 23(3):480-4. PubMed ID: 7515994
    [Abstract] [Full Text] [Related]

  • 13. Disparate effects of calcium antagonists on renal microcirculation.
    Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T.
    Hypertens Res; 1996 Mar 16; 19(1):31-6. PubMed ID: 8829821
    [Abstract] [Full Text] [Related]

  • 14. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.
    Arch Intern Med; 2005 Apr 25; 165(8):936-46. PubMed ID: 15851647
    [Abstract] [Full Text] [Related]

  • 15. Influence of the timing of initiating antihypertensive therapy in hypertensive rats with renal failure.
    Kanno Y, Okada H, Takenaka T, Saruta T, Suzuki H.
    Clin Exp Hypertens; 2000 Jul 25; 22(5):521-9. PubMed ID: 10937842
    [Abstract] [Full Text] [Related]

  • 16. Characterization of the renal action of pranidipine in the rat.
    Nagahama T, Hayashi K, Fujiwara K, Ozawa Y, Saruta T.
    Arzneimittelforschung; 2000 Mar 25; 50(3):248-53. PubMed ID: 10758776
    [Abstract] [Full Text] [Related]

  • 17. Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
    Morimoto S, Yano Y, Maki K, Iwasaka T.
    J Hypertens; 2007 Oct 25; 25(10):2178-83. PubMed ID: 17885563
    [Abstract] [Full Text] [Related]

  • 18. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up.
    Kanno Y, Okada H, Saruta T, Suzuki H.
    Clin Nephrol; 2000 Nov 25; 54(5):360-5. PubMed ID: 11105796
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Role of protein kinase C in Ca channel blocker-induced renal arteriolar dilation in spontaneously hypertensive rats--studies in the isolated perfused hydronephrotic kidney.
    Hayashi K, Wakino S, Ozawa Y, Homma K, Kanda T, Okubo K, Takamatsu I, Tatematsu S, Kumagai H, Saruta T.
    Keio J Med; 2005 Jun 25; 54(2):102-8. PubMed ID: 16077260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.